Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust?
- 28 February 2005
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 32 (1), 69-75
- https://doi.org/10.1053/j.seminoncol.2004.09.035
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II studyInternational Journal of Cancer, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerNew England Journal of Medicine, 2003
- COX-2, Inflammatory Secreted PLA2, and Cytoplasmic PLA2 Protein Expression in Small Bowel Adenocarcinomas Compared with Colorectal AdenocarcinomasLaboratory Investigation, 2003
- Interstitial cell cyclooxygenase‐2 expression is associated with increased angiogenesis in human sporadic colorectal adenomasThe Journal of Pathology, 2002
- Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cellsOncogene, 2002
- Human colorectal adenomas demonstrate a size‐dependent increase in epithelial cyclooxygenase‐2 expressionThe Journal of Pathology, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Low-Dose Aspirin and Incidence of Colorectal Tumors in a Randomized TrialJNCI Journal of the National Cancer Institute, 1993